| 非M3型急性髓系白血病细胞遗传学及分子生物学特征和预后分析 |
| |
| 引用本文： | 熊术道,胡林辉,蒲莲芳,丁洋洋,李曼曼,刘军,杨冬冬,王会平,张翠.非M3型急性髓系白血病细胞遗传学及分子生物学特征和预后分析[J].安徽医药,2016,20(9):1727-1730. |
| |
| 作者姓名： | 熊术道 胡林辉 蒲莲芳 丁洋洋 李曼曼 刘军 杨冬冬 王会平 张翠 |
| |
| 作者单位： | 安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601,安徽医科大学第二附属医院血液科 血液病实验室 安徽医科大学血液病研究中心,安徽 合肥 230601 |
| |
| 基金项目： | 国家自然科学基金(81272259)非M3型急性髓系白血病细胞遗传学及分子生物学特征和预后分析熊术道,胡林辉,蒲莲芳,丁洋洋,李曼曼,刘军,杨冬冬,王会平,张翠 (安徽医科大学第二附属医院血液科血液病实验室安徽医科大学血液病研究中心,安徽 合肥 230601)非M3型急性髓系白血病细胞遗传学及分子生物学特征及预后分析 熊术道,胡林辉,蒲莲芳,等 |
| |
| 摘 要： | 目的 探讨和分析非M3型急性髓系白血病(AML)细胞遗传学及分子生物学特征以及预后影响因素。方法 回归性分析99例非M3型初治AML患者临床及实验室数据,探讨和分析患者性别、年龄、初诊时白细胞数、血小板数、有无贫血、乳酸脱氢酶水平、染色体核型以及融合基因等因素对AML患者无疾病进展生存时间(DFS)及总体生存时间(OS)的影响。结果 患者中位发病年龄为44岁(1~84岁),中位随访时间为12.6月(0.33~59.47月),化疗后达完全缓解(CR)率为62.7%,复发率为44.1%,不同年龄段患者CR率有明显差异(P=0.035)；单因素及多因素分析显示老年及染色体数目异常为AML患者OS的独立预后不良因素,t(8,1)/inv(16)系其独立预后良好因素。结论 老年及染色体数目异常为非M3型AML患者独立预后不良因素；t(8,1)/inv(16)是其独立预后良好因素。AML临床应结合年龄、细胞遗传学及分子生物学等预后因素进行预后评估,据此制定个体化治疗,对延长患者生存时间,提高生活质量,具有重要指导意义。
|
| 关 键 词： | 白血病 髓样 急性 核型 基因融合 危险因素 预后 |
| 收稿时间： | 2016/4/18 0:00:00 |
| 修稿时间： | 2016/6/12 0:00:00 |
Cytogenetics and molecular biology characteristics and prognosis of de novo non-M3 acute myeloid leukemia |
| |
| Institution: | Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China,Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China and Department of Hematology/Hematological Lab,The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230601,China |
| |
| Abstract: | Objective To investigate the changes of cytogenetics and molecular biology in patients with de novo non-M3 acute myeloid leukemia(AML),and to explore the related factors of prognosis for AML patients.Methods Ninety-nine cases of newly diagnosed de novo non-M3 AML were enrolled in this study.The relationship between disease free survival(DFS),overall survival(OS) and clinical and laboratory data of all AML patients,including gender,age,WBC counts,PLT counts,Hb values,LDH level,chromosome karyotype and fusion gene were retrospectively analyzed.Results The median age of 99 patients with AML in this study was 44(1~84) years old.The median follow-up was 12.6(0.33~59.47) months,the total complete remission(CR) rate was 62.7% and relapse incidence was 44.1%.CR rate was influenced by factors such as age(P=0.035).Univariate and multivariate analyses showed that the factors including age and numerical abnormalities of chromosomes were the independent unfavorable prognostic factors while t(8,1)/inv(16) was an independent favorite one for OS in patients with de novo non-M3 AML.Conclusions Both elderly patients and changed chromosome numbers are the independent poor prognostic factors in patients with de novo non-M3 AML,while t(8,1)/inv(16) is an independent favorite one.So the patients with de novo non-M3 AML should be treated with individual therapy according to the prognostic prediction,which then may prolong the survival time and improve the quality of life. |
| |
| Keywords: | Leukemia myeloid acute Karyotype Gene fusion Risk factors Prognosis |
|
| 点击此处可从《安徽医药》浏览原始摘要信息 |
| 点击此处可从《安徽医药》下载免费的PDF全文 |
|
